IRVINE, CA / ACCESSWIRE / September 20, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE: RDY). Investors who purchased or otherwise acquired shares between June 17, 2015 and August 10, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before the October 24, 2017 lead plaintiff motion deadline.
If you purchased Dr. Reddy's shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 4000 Barranca Parkway, Suite 250, Irvine, CA 92604, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member as well.
According to the Complaint, throughout the Class Period, Dr. Reddy's made false and/or misleading statements, and/or failed to disclose, that it lacked an effective corporate quality system; and thus, its public statements were materially false and misleading at all relevant times. On August 10, 2017, the Company disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices compliance certificate of a formulations manufacturing unit of its German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. When this news was announced, shares of Dr. Reddy's lowered in value materially, which caused investors harm according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone at (949) 419-3834, or via e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com
SOURCE: Khang & Khang LLP
